LGVNHealthcare · BiotechnologyThe 3 Wall Street analysts covering Longeveron, Inc. hold a median 12-month price target of $80 — +991.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Longeveron, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (85): Smaller than most of the companies we track.
Value (18): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LGVN, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +991.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | Maxim Group | Downgrade | Hold | — |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $8.00 |
| 15 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | Roth MKM | Initiates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2024 | Maxim Group | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 July 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 1 June 2023 | EF Hutton | Assumes | Buy | $13 |
| 16 May 2023 | EF Hutton | Reiterates | Buy | — |
| 9 May 2023 | EF Hutton | Reiterates | Buy | — |
| 27 Mar 2023 | EF Hutton | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LGVN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 10% of US stocks
Cheaper than 45% of US stocks
Cheaper than 64% of US stocks
Higher than 16% of US stocks
Higher than 27% of US stocks
Higher than 77% of US stocks
Higher than 4% of US stocks
Higher than 98% of US stocks
Higher than 7% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Longeveron, Inc. has a market value of $21.2M and an enterprise value of $11.7M.
Revenue in the twelve months to 30 June 2026: $1.2M. The latest quarter shrank 9.2% year on year.
Net income over the same four quarters: −$23.5M, a −1977.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$20.7M.
Trailing P/E: 2.9×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Longeveron, Inc. employs 38 people — $31K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Longeveron, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Longeveron announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026. The company's presentation is scheduled for September 14, 2026 at 1:00pm ET.
Why it matters — This gives LGVN watchers an opportunity to hear the company's latest updates at a notable investment conference.
Longeveron announced a 1-for-10 reverse split of its Class A and Class B common stock. The split was previously approved by stockholders at the company's annual meeting on July 1, 2026, and by the Board of Directors on July 31, 2026.
Why it matters — A reverse stock split changes the share structure and per-share price of LGVN stock, which shareholders and watchers would want to track.
Longeveron announced the appointment of Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, succeeding Marie Washburn who had stepped into the role after the prior CFO's retirement. Jhaveri brings over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector.
Why it matters — A new CFO with extensive biotech and capital markets experience joins Longeveron's executive leadership team, which could be relevant to investors following the company's financial management and strategic direction.
Longeveron Inc. held its Q2 2026 earnings call, and Seeking Alpha published the corresponding transcript of the management discussion.
Why it matters — LGVN watchers can review the transcript for the company's own commentary on its second-quarter results and operations.
Longeveron reported financial results for the quarter ended June 30, 2026, and provided a business update. The company said it remains on track for September 2026 top-line results from its Phase 2b clinical trial (ELPIS II) of laromestrocel for hypoplastic left heart syndrome, noted its selection as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition, and announced three new independent directors joining its Board.
Why it matters — LGVN watchers would care because the update confirms progress on its key Phase 2b trial timing for laromestrocel while also highlighting new recognition and board changes that could signal the company's trajectory.
The 3 Wall Street analysts covering Longeveron, Inc. have a median 12-month price target of $80, with estimates ranging from $30 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Longeveron, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Longeveron, Inc. 30 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 11 Sept 2026, Longeveron, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +991.4% from the last close, and Ticker Nerd's factor model ranks Longeveron, Inc. 30 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Longeveron, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $105 over the next 12 months.
Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies.
The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Longeveron announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026. The company's presentation is scheduled for September 14, 2026 at 1:00pm ET.
Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions. Its current programs center on Lomecel-B, a lead investigational therapy being studied across several clinical indications, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron’s work spans cell therapy research, clinical development, and translational medicine, placing it within the broader biotechnology sector. Headquartered in Miami, Florida, Longeveron serves as a specialized player in the market for advanced biological treatments aimed at unmet medical needs.
CEO Mr. Stephen H. Willard Esq. · 38 employees · United States · https://longeveron.com